Latest news with #KevinSayer
CNBC
05-08-2025
- Business
- CNBC
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
Yahoo
05-08-2025
- Business
- Yahoo
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change
We recently published . DexCom, Inc. (NASDAQ:DXCM) is one of the companies that stood stronger last week. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company's strong earnings performance in the second quarter of the year. In a statement last week, DexCom, Inc. (NASDAQ:DXCM) named Jake Leach as its new chief executive officer (CEO) effective January 1, 2026, in addition to his post as the current president and chief operating officer. Incumbent CEO Kevin Sayer will continue to work closely with Leach during the transition period and remain executive chairman of the board of directors. Meanwhile, DexCom, Inc. (NASDAQ:DXCM) grew its net income in the second quarter of the year by 25 percent to $179.8 million from $143.5 million in the same period last year. Revenues increased by 16 percent to $1.16 billion from $1 billion year-on-year. While we acknowledge the potential of DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-08-2025
- Business
- Yahoo
Dexcom CEO Kevin Sayer to step down
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom CEO Kevin Sayer will step down after leading the diabetes tech company for a decade. Current Chief Operating Officer Jake Leach will become CEO on Jan. 1, 2026, and join the firm's board of directors, according to a Wednesday announcement. Sayer will help with the transition and remain executive chairman of Dexcom's board of directors. Sayer said in a statement that the decision was the result of the board's succession planning and confidence that Leach is the right leader to continue the company's growth. 'There is nobody that I trust more than Jake to lead the company into the future,' Sayer told investors on a Wednesday earnings call. Leach has worked at Dexcom for 21 years, since the company launched its first product. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. Dexcom, which makes continuous glucose monitors, has faced growing competition in the sector, as Abbott expands integrations with automated insulin delivery systems and the Food and Drug Administration authorizes longer-lasting implantable sensors. Dexcom and Abbott last year launched the first over-the-counter glucose sensors. BTIG analyst Marie Thibault said Leach's appointment is not a surprise, as he has been promoted multiple times and has become more visible to investors. J.P. Morgan analyst Robbie Marcus added that the change had been telegraphed for some time. Still, 'there's always some nervousness following the retirement of a long-time CEO,' Marcus wrote. 'Especially one that has transformed a company and product category while creating significant shareholder value like Kevin did.' When asked about his vision for Dexcom as a new CEO, Leach said he is looking to expand global access to the company's devices. 'We're seeing good progress in our growth globally, but there's so much more to do in terms of gaining access for people around the globe that could benefit from our technology,' Leach said. Leach also listed continued innovation as a priority, with a focus on features that benefit the Dexcom's users as the company reaches a broader group of people. At the end of Wednesday's call, Sayer reiterated that he will still be involved with Dexcom for the next five months and plans to set up the company's new leaders for success. 'I'm not riding the retirement wave out of here,' Sayer said. Editor's note: This article has been updated with additional details and comments from analysts. Recommended Reading Dexcom COO on 15-day glucose sensor, Type 2 coverage Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year's revenue to be around $4.6 billion, close to analysts' estimates. Its non-GAAP profit of $0.32 per share was in line with analysts' consensus estimates. Is now the time to buy DXCM? Find out in our full research report (it's free). Revenue: $1.04 billion vs analyst estimates of $1.02 billion (12.5% year-on-year growth, 1.8% beat) Adjusted EPS: $0.32 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $230.4 million vs analyst estimates of $251.9 million (22.2% margin, 8.5% miss) The company reconfirmed its revenue guidance for the full year of $4.6 billion at the midpoint Operating Margin: 12.9%, up from 11% in the same quarter last year Free Cash Flow Margin: 9.3%, down from 16.5% in the same quarter last year Organic Revenue rose 13.8% year on year (24.8% in the same quarter last year) Market Capitalization: $33.93 billion DexCom's first quarter results reflected ongoing momentum in its core continuous glucose monitoring (CGM) business, with management attributing growth to expanded commercial reach, increased patient starts—particularly among type 2 non-insulin users—and new product enhancements. CEO Kevin Sayer cited record levels of new customer acquisition, driven by broadened prescriber activity and new payer access wins, as well as the recent launch of Stelo, DexCom's over-the-counter biosensor, and updates to the G7 platform. Looking forward, management underscored the importance of continued payer coverage expansion, particularly with all three major pharmacy benefit managers (PBMs) now committed to covering DexCom's G7 for wider patient populations. CFO Jereme Sylvain emphasized the company's focus on managing supply chain costs and margin pressures, while maintaining investment in product innovation and operational efficiency. Sayer stated, 'We believe we can continue to demonstrate our value time and time again,' highlighting DexCom's efforts to secure broader access, data-driven outcomes, and regulatory clearances. DexCom's management provided detailed context on the drivers of first quarter performance and addressed several business-critical developments impacting the outlook for 2025. Type 2 Diabetes Access Gains: Management emphasized that recent wins with large PBMs have accelerated adoption among type 2 non-insulin users. The company saw a notable uptick in new patient starts from this population, which is now a material portion of overall new additions. Stelo Launch and Uptake: The over-the-counter Stelo sensor, targeting type 2 diabetes, prediabetes, and wellness users, continues to attract new customers. Stelo's app enhancements and expanded distribution, including availability on Amazon, have driven over 200,000 downloads to date. 15-Day G7 System Clearance: DexCom secured FDA approval for a 15-day wear G7 sensor, increasing convenience and potentially improving margins. The product is slated for launch in the second half of the year, with work underway to ensure compatibility with insulin pumps and payer coverage. Operational and Supply Dynamics: The company navigated short-term supply constraints by expediting shipments and working closely with distribution partners. Management acknowledged incremental freight costs but confirmed that manufacturing output and product quality have stabilized. FDA Warning Letter Response: DexCom addressed an FDA warning letter received in March, implementing corrective process controls without impacting new product approvals or ongoing distribution. Management expects to resolve outstanding issues while continuing to prioritize innovation. Management's outlook for 2025 centers on broadening access for DexCom's CGM products, scaling adoption among type 2 diabetes patients, and improving operational efficiency amid cost pressures. Broader Payer Coverage: Coverage expansion among major PBMs is expected to drive growth in the type 2 non-insulin segment, unlocking a larger addressable market and supporting continued high rates of new patient acquisition. Product Pipeline Execution: The upcoming launch of the 15-day G7 sensor and ongoing software enhancements—such as Stelo app updates and integration with third-party wellness platforms—are positioned to support retention, differentiation, and margin improvement over time. Margin Management and Cost Controls: Management highlighted ongoing programs to offset elevated freight costs and inflationary pressures, including leveraging prior investments in automation, AI, and sales force expansion. The ability to balance investment with efficiency is seen as key to maintaining operating margins despite external headwinds. Matt Taylor (Jefferies): Asked about the closure of the gap between volume and revenue growth. Management confirmed inventory normalization and record new patient starts, indicating that volume growth remains robust and consistent with earlier trends. Larry Biegelsen (Wells Fargo): Questioned why full-year guidance was unchanged despite strong Q1 organic growth. CFO Jereme Sylvain said it was too early to adjust guidance after one quarter, emphasizing a commitment to deliver on full-year targets. Danielle Antalffy (UBS): Sought insight on DexCom's resilience in a potential recession. Management cited strong payer coverage and the cost-saving value of CGM to health systems, expressing confidence in the company's positioning relative to peers. Jeff Johnson (Baird): Inquired about gross margin cadence and whether manufacturing issues persisted. Management stated margin improvement is expected later in the year and indicated that manufacturing output and quality are on track, with no ongoing process issues. Jayson Bedford (Raymond James): Probed on international revenue softness and supply dynamics. Management noted localized strength in Japan and France but acknowledged timing variability in international coverage wins, resulting in some quarterly choppiness. Looking ahead, the StockStory team will monitor (1) execution of the 15-day G7 system launch and its adoption rates, (2) continued expansion of coverage for type 2 non-insulin diabetes patients among payers, and (3) the pace at which supply chain costs normalize and margins recover. Additional signposts include data readouts from the type 2 diabetes randomized controlled trial and further growth in Stelo's user base. DexCom currently trades at a forward P/E ratio of 40×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Why DexCom, Inc. (DXCM) Went Up On Friday
We recently published a list of In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other Friday's top performers. The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more corporate earnings results. The tech-heavy Nasdaq led the rally among all major indices, finishing up by 1.51 percent. The S&P 500 clocked in a 1.47-percent gain, while the Dow Jones grew by 1.39 percent. Ten companies also mimicked the broader market optimism following impressive earnings performance and an optimistic outlook for the rest of the year. In this article, we have identified the 10 top performers on Friday and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A doctor demonstrating how to use the medical device to a patient with diabetes. Dexcom Inc. surged by 16.17 percent on Friday to end at $81.62 apiece after reporting an impressive 12.49 percent revenue growth in the first quarter of the year and maintaining outlook guidance for the rest of 2025. In a statement, DexCom, Inc. (NASDAQ:DXCM) said that revenues improved to $1.036 billion in the past three months from the $921 million registered in the same period last year. Net income, however, declined by 28 percent to $105.4 million from $146.4 million in the same comparable period. 'As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15-Day system and continue to advocate for expanded global access to our glucose biosensors,' said DexCom, Inc. (NASDAQ:DXCM) CEO Kevin Sayer. Looking ahead, the company expects full-year revenues to increase by 14 percent to $4.6 billion, and adjusted EBITDA margin to expand by 30 percent year-on-year. Overall, DXCM ranks 6th on our list of Friday's top performers. While we acknowledge the potential of DXCM as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than DXCM but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
